As part of its commitment to safety of the patients, Organigram Holdings Inc (CVE:OGI) posted that, effective May 12, the Certificates of Analysis for its products will be made accessible to those patients that are registered within firm’s web outlet. Certificates will be given as and when they are introduced. To refer to reports, the patient needs to first select a strain by logging into the web portal. Certificates of analysis are exhibited underneath the product’s details.
Organigram posted that the Certificates of Analysis will show client sample ID. Each lot of medical cannabis items that the firm manufacturers gets a distinct lot number for the purpose of traceability. The items will show the acceptability tests details carried out on the batch. This part sketches the element or organism being considered for deciding if the goods are safe for use.
Commenting on the mechanism, Organigram posted that the certificate of analysis will exhibit authorized process applied by the lab for testing. It will exhibit the tolerance limit. The chemical as well as microbial contaminants in product must lie within approved tolerance limits for human consumption as prescribed in any publication as per Schedule ‘B’ to the U.S. FDA finalized by the Licensed Manufacturer.
Organigram has closed on the European Pharmacopeia. For illustration, colony forming component a gram, most likely number a gram, nanograms/gram, milligrams/kilogram and the list goes on. Also, the final result of the performed tests will be exhibited on certificate.
If the conclusion is under the accepted tolerance limit, it is agreed “pass” and itemized safe for consumption. Analysis is done for cannabinoid profile, which is more or less a breakdown of the different Cannabinoids available within the product.
In the last trading session, the stock price of declined 0.78% to close the day at $2.56. After the last decline, the market cap of firm stands at around $289 million.